{"entity":{"id":"ret01","kind":"drug","name":"ReT01 ACT","aka":["ReT01","Re-TIL"],"tldr":"ReT01 ACT is an experimental autologous tumour-infiltrating lymphocyte cell therapy from Beijing Xunsheng Biomedical Research, in phase 1 trials for advanced cervical cancer after failure of first-line systemic therapy and advanced solid tumours.","summary":"ReT01 ACT (ReT01, Re-TIL) is an autologous tumour-infiltrating lymphocyte (TIL) cell therapy from Beijing Xunsheng Biomedical Research. TILs grown from the patient's own tumour tissue by the company's activation and expansion process and infused back; the company says it is given without lymphodepletion and without IL-2 injection. Its furthest stage is phase 1, for advanced cervical cancer after failure of first-line systemic therapy and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 in advanced solid tumours recruiting (NCT06257680); company recruitment page says 临床 Ⅱ 期 for cervical cancer, but no phase 2 registry record was found, so phase 1 is used. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Beijing Xunsheng Biomedical Research: aeonvital.com","url":"http://www.aeonvital.com/page141"},{"label":"Beijing Xunsheng Biomedical Research: aeonvital.com","url":"http://www.aeonvital.com/page139"},{"label":"Beijing Xunsheng Biomedical Research: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06257680"},{"label":"ClinicalTrials.gov: trials of ReT01","url":"https://clinicaltrials.gov/search?intr=ReT01"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["beijing-xunsheng-biomedical"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06257680"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ReT01","modality":"Autologous tumour-infiltrating lymphocyte (TIL) cell therapy","mechanism":"TILs grown from the patient's own tumour tissue by the company's activation and expansion process and infused back; the company says it is given without lymphodepletion and without IL-2 injection.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ret01/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"beijing-xunsheng-biomedical","kind":"company","name":"Beijing Xunsheng Biomedical Research","route":"/companies/beijing-xunsheng-biomedical/"}],"trial":[{"id":"nct06257680","kind":"trial","name":"A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors","route":"/trials/nct06257680/"}]}}